Get the Stockscreener App
5.62
1.13%
0.29
After Hours:
5.62
Casi Pharmaceuticals Inc stock is traded at $5.62, with a volume of 18,323.
It is up +1.13% in the last 24 hours and down -3.41% over the past month.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
See More
Previous Close:
$5.33
Open:
$5.4778
24h Volume:
18,323
Relative Volume:
0.68
Market Cap:
$85.65M
Revenue:
$33.88M
Net Income/Loss:
$-26.94M
P/E Ratio:
-1.8859
EPS:
-2.98
Net Cash Flow:
$-26.70M
1W Performance:
-3.58%
1M Performance:
-3.41%
6M Performance:
+63.33%
1Y Performance:
+17.17%
1-Day Range:
$5.26
$5.6899
1-Week Range:
$5.21
$5.95
52-Week Range:
$2.05
$8.48
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Name
Casi Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare CASI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CASI | 5.62 | 85.65M | 33.88M | -26.94M | -26.70M | -2.98 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Initiated | Mizuho | Buy |
| Oct-23-20 | Initiated | Oppenheimer | Outperform |
| Sep-22-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
View All
Casi Pharmaceuticals Inc Stock (CASI) Latest News
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - AccessWire
CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan
CASI Pharmaceuticals Inc (CASI) Quarterly 10-Q Report - Quartz
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - GuruFocus.com
CASI Pharmaceuticals gets China nod for ITP treatment trial - Investing.com
CASICASI Pharmaceuticals, Inc. Ordinary Shares Latest Stock News & Market Updates - StockTitan
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - AccessWire
CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update - MarketBeat
Objective long/short (CASI) Report - Stock Traders Daily
Renaissance Technologies LLC Acquires 4,000 Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) - Defense World
(CASI) Trading Report - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.67 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.67 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week - Yahoo Finance
CASI Pharmaceuticals (NASDAQ:CASI) pulls back 22% this week, but still delivers shareholders solid 129% return over 1 year - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Passes Above 200 Day Moving Average of $4.60 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above Two Hundred Day Moving Average of $4.60 - Defense World
Tumor Necrosis Factor Inhibitor Drugs Market Insights Discussed Regarding Trends and Forecast Report 2024-2033 - WhaTech
CASI Pharmaceuticals (NASDAQ:CASI) Shares Pass Above 200 Day Moving Average of $4.57 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Crosses Above 200-Day Moving Average of $4.57 - MarketBeat
(CASI) Investment Report - Stock Traders Daily
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - BioSpace
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200 Day Moving Average of $4.48 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above 200-Day Moving Average of $4.48 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Passes Above 200-Day Moving Average of $4.46 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.46 - MarketBeat
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 6.9% - Defense World
(CASI) Technical Pivots with Risk Controls - Stock Traders Daily
CASI Pharmaceuticals (NASDAQ:CASI) Announces Quarterly Earnings Results - Defense World
Idg Accel China Growth Fund Iii L.p. Net Worth (2024) - GuruFocus.com
CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 - MSN
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PR Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above 200 Day Moving Average of $4.47 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Share Price Crosses Above Two Hundred Day Moving Average of $4.47 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above Two Hundred Day Moving Average of $4.44 - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Stock Passes Above 200-Day Moving Average of $4.44 - MarketBeat
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com - Defense World
3 Promising Biotech Stocks You Can Pick Up for Less Than $10 - InvestorPlace
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Sees Large Decline in Short Interest - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200-Day Moving Average of $4.41 - MarketBeat
CASI Pharmaceuticals (NASDAQ:CASI) Stock Price Crosses Above 200 Day Moving Average of $4.41 - Defense World
Casi Pharmaceuticals Inc Stock (CASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.27%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):